Vera Therapeutics (VERA) Citi Annual Global Healthcare Conference 2025 summary

Recent clinical data and regulatory progress

• Positive Phase III data for Atakicept in IgAN nephropathy presented at ASN and published in NEJM; BLA filed in November with potential PDUFA date in July.

• Atakicept received breakthrough designation, with review timelines of two plus six months in the cardiorenal division.

• Two-year efficacy data published, showing stabilization of kidney function and strong safety profile.

• Long-term extension studies and open-label programs are ongoing to assess durability and broader patient impact.

• Commercial launch preparations are advanced, with autoinjector expected at launch and experienced leadership in place.

Clinical impact and patient benefit

• Atakicept demonstrated the ability to maintain GFR similar to healthy individuals and reduce proteinuria and hematuria.

• Safety profile is comparable to placebo, with no increased risk of infections, even during the COVID-19 pandemic.

• Therapy targets B cells via dual BAF-APRL inhibition, offering a novel, precise approach to autoimmunity.

• Patients may see a significant reduction in the risk and delay of end-stage kidney disease, improving long-term outcomes.

• Hope for chronic disease management without the need for dialysis or transplant is a key patient message.

Competitive landscape and differentiation

• Five drugs are approved for IgAN; Atakicept is the first dual BAF-APRL inhibitor and only program with two-year GFR data.

• Recent competitor approval targets APRL only, but Atakicept offers broader mechanism and autoinjector convenience.

• Neutralizing antibodies affecting efficacy have been noted in competitor programs.

• Atakicept is positioned as a foundational, disease-modifying therapy in nephrology.